RxDoctor Payments Data

Anny Kim, OD

Optometrist · New Castle, DENPI 1588615926

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.2% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $495 and has fallen 56.6% since, to $215 in 2025.

$2,071in general payments, 2019–2025

Across 63 payments — averaging $32.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$425
  • Coopervision Inc.$419
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$400
  • Alcon$176
  • Johnson & Johnson Vision Care, Inc.$154
  • Oyster Point Pharma, Inc.$129
  • plus $368 from 7 others

What the payments were for

  • Food & beverage$2,03598%
  • Gifts$372%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,071 in reported general payments places this provider in the 85th percentile of 146 optometrist providers in Delaware.

See all optometrist providers in Delaware

Medicare billing

Part B allowed, 2024
$121,414
Medicare patients
659
Services billed
1,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost25$11,495
Travoprost25$4,914
Latanoprost196$3,069
Brimonidine Tartrate15$3,049
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat32$523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$108$11,49525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 146 optometrist providers in Delaware.

Other optometrist in New Castle

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →